Logo
Media
Media

Media

Rigontec GmbH raises €9.45m

Rigontec GmbH raises €9.45m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases Bonn, Germany. 14th October 2014 – Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treat...

Continue reading ...